Nexthera Capital’s Tvardi Therapeutics TVRD Stock Holding History

Nexthera Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,481	Closed	-$17.7M	–	46
2018 Q3	$17.7M	Buy	20,481 +8,375	+69%	+$6.05M	3.38%	10
2018 Q2	$8.35M	Buy	12,106 +2,355	+24%	+$1.2M	1.29%	24
2018 Q1	$4.35M	Buy	+9,751	New	+$4.73M	0.72%	31
2017 Q2	–	Sell	-3,333	Closed	-$2.11M	–	47
2017 Q1	$2.21M	Sell	3,333 -3,611	-52%	-$1.93M	1.13%	21
2016 Q4	$2.32M	Buy	+6,944	New	+$2.23M	1.36%	21

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nexthera Capital's TVRD Position: Q4 2018 in Review

Nexthera Capital sold out of Tvardi Therapeutics (TVRD) in Q4 2018, closing a stake of 20,481 shares — an estimated $17.7M sold.

Nexthera Capital first reported a position in TVRD in Q4 2016 and held it in 5 quarters. The position peaked at $17.7M in Q3 2018. 134 funds tracked by Wall St. Rank hold TVRD as of Q4 2018.

Nexthera Capital reported no remaining Tvardi Therapeutics position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 20,481 Tvardi Therapeutics shares in Q4 2018, an estimated $17.7M.
Nexthera Capital first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 5 quarters.
Nexthera Capital's Tvardi Therapeutics position peaked at $17.7M in Q3 2018.
134 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.